Defective Drug Lawsuit Loans

Defective drug lawsuit loans are for people whose drug injury case is filed by a lawyer or already settling.

An advance of $500 to $250,000+ is possible. It’s non-recourse, so a lost case wipes the balance out.

Apply online or phone us; we’ll sort out the details with your lawyer.

Defective drug lawsuit loans for people harmed by a dangerous prescription drug

Do I qualify?

Yes, if a lawyer has filed your drug injury case.

  • You have a lawyer who’s likely paid from a share of any win.
  • Your lawsuit is filed, or a settlement agreement is in progress.
  • Your records show you took the drug and then had a serious injury linked to it.
  • The case was brought in a state we fund. Moving it into an MDL (similar federal cases grouped before one judge) later doesn’t change that.

People call it a lawsuit loan. It’s a non-recourse advance, not a loan: if you lose, you owe nothing.

Credit, income and work history play no part. A drug claim targets the maker, not your doctor. If a doctor’s mistake hurt you, our sister brand, ECO Pre-Settlement Funding, handles that kind of case.

How it works

Drug cases rest on records: what you took, when you took it and what happened next. Your lawyer has those, so that’s where we start.

1. Apply

Use our short form or call us, and include your lawyer’s name and number. Tell us which drug the case is about.

2. Your lawyer sends the file

They share the filing, your medical records and the case’s status. Our answer waits on their reply.

3. See the terms

If we can fund, you get a short contract in plain words. Your lawyer can walk you through it before you sign.

4. Money in hand

We send the money straight to you. We’re repaid from the settlement, through your lawyer, and only if the case pays.

What Matters for Defective Drug Lawsuit Loans

A drug injury claim is a product liability case against the drug maker. Cases over one drug are often grouped as a mass tort (many people hurt by the same product or exposure). Your claim keeps its own value inside the group.

This is true whether a doctor prescribed the drug or you bought it at a store.

The fight is over the warning

Most drug cases ask what the company knew about a risk and whether it told patients and the FDA. Proving that takes expert witnesses and years. The claims are still being tested in court; none is proven.

The filing state decides

We fund cases filed in 41 states, and the state guide names them. If your case moved into an MDL, the court where it was first filed decides. Two MDLs on this page sit in Illinois, but cases sent there from a state we fund still qualify.

Records we ask for

Expect us to ask for proof you took the drug, like pharmacy records, and a diagnosis that fits the case. We also ask whether you’re in a settlement or still fighting. Some people opt out (leave the group deal and keep suing), and we ask about that too.

If you’re already in a deal

Many drug deals score each claim, then pay by tier. Once you’re enrolled, we look at your likely award and when it should be paid. Your lawyer’s estimate of that award carries the most weight.

What lowers the amount

A drug that’s hard to tie to your injury lowers the number. A health plan or Medicare lien (money that must be paid back from the settlement first) shrinks what you net. If your deal is nearly paid, a small advance or none may serve you better.

Why these cases take so long

Drug makers can afford to wait, and these cases often last three to five years, sometimes longer. An advance takes the pressure off, so you’re not forced into an early, low deal.

New to funding? See what pre-settlement loans are and why non-recourse funding matters.

Drugs With Active Lawsuits We Fund

These drug cases are active in 2026. Each one is still being argued in court, and the list changes as cases open and close.

Ozempic & GLP-1 Drugs

Ozempic, Wegovy, Mounjaro and Trulicity, tied in lawsuits to stomach paralysis and bowel blockage. Other claims cite sudden vision loss. Over 4,000 cases sit in a federal MDL.

Depo-Provera

The birth control shot linked in lawsuits to brain tumors called meningiomas after long use. The FDA added a warning in 2025. Over 6,000 claims are in a federal MDL.

Suboxone

The opioid treatment film said to cause severe tooth decay. Claims say its acid content and its warnings fell short. About 1,800 cases are in a federal MDL.

Tepezza

The thyroid eye drug tied in lawsuits to lasting hearing loss and ringing in the ears. Its federal MDL sits in Illinois. Cases first brought in a state we fund still qualify after the move.

Tylenol (Acetaminophen)

Lawsuits claim that using it while pregnant is tied to autism and ADHD. Federal cases were thrown out, then revived on appeal in 2026.

Zantac (Ranitidine)

The heartburn drug said to break down into NDMA, a likely cause of cancer. Federal claims were dismissed, but state court cases and deals go on.

We also fund other active drug claims. That includes valsartan and other blood pressure drugs tainted with NDMA, and new drug cases as courts group them. Settled but unpaid Elmiron claims can qualify too.

Nexium, Elmiron and Paraquat: Where Each One Stands

Many older drug cases, like Pradaxa, Xarelto and Actos, have settled or closed. Talc is a cosmetic, not a drug, so it has its own talcum powder funding page. The cases we fund hub lists every other type.

Nexium, Elmiron and paraquat once had their own pages. Two are winding down and one is very much alive, so the funding answer differs for each.

Nexium and Other PPIs: Settled, Still Paying Out

Status as of September 2026.

The kidney injury cases over heartburn drugs called PPIs ran in a federal MDL in New Jersey. In October 2023, AstraZeneca announced a $425 million deal for Nexium and Prilosec claims, with no admission of fault.

Takeda says it signed a final deal for its Prevacid and Dexilant cases in November 2024. Lead lawyers for the plaintiffs say the other makers settled too.

So why does the September 1, 2026 federal tally still list 11,404 PPI cases? A settled case stays open until it’s scored, liens are cleared and the check goes out.

Who can get funding: people who filed and are waiting on payment, plus the few still in the fight. We ask your lawyer for your status, your award level and any money held back for liens. We know of no firms taking new PPI kidney clients, so an unfiled claim has nothing to fund.

Elmiron: Settling Quietly, Closed to New Claims

Status as of September 2026.

Elmiron is a bladder pain drug tied to a retina disease that can cause lasting vision loss. The cases against Janssen went to a federal MDL in New Jersey. No test trial was ever held.

Cases settle firm by firm, in private, and no one has published a total. Be wary of any site that quotes one. The September 2026 count shows 286 cases pending of 1,988 filed.

Lawyers say most of what’s left has settled and is waiting on payment, and no firms are taking new clients. We can fund an unpaid award or a signed release (the paper you sign to accept a settlement). These advances are short, since the wait is for paperwork, not a trial.

Paraquat: Active, Large and on Several Tracks

Status as of September 2026.

Paraquat is a restricted weed killer that thousands of farmers and rural workers blame for Parkinson’s disease. The defendants are Syngenta and Chevron.

The federal MDL sits in southern Illinois, with 6,666 cases pending of 8,488 filed. In April 2025, lead lawyers signed a deal meant to resolve many of them. The amount isn’t public, and no per-person figures exist.

The court paused deadlines while the deal took shape. In 2026 it has dealt with many plaintiffs who opted out and want a trial.

Other cases sit in the Philadelphia Court of Common Pleas. The first test case there settled on the eve of trial in January 2026. More are grouped in California state court.

Who can get funding: anyone with Parkinson’s whose paraquat case began in a state we fund. That covers cases moved into the federal MDL and those in Philadelphia or California, in the deal or not.

Opt-out cases carry more risk and delay, and we review them that way. Our paraquat funding guide goes deeper.

Questions About Defective Drug Lawsuit Loans

For general cost and contract answers, visit the main FAQ.

Are defective drug lawsuit loans real loans?

No. It’s an advance on your claim, paid back out of any recovery. No monthly bills come, and a lost case means you owe nothing.

Which drugs can I get funding for?

Any drug claim your lawyer has filed, still being fought or settled but not yet paid. That includes Ozempic and other GLP-1 drugs, Depo-Provera, Suboxone, Tepezza, Tylenol, Zantac and the sartan blood pressure drugs. The list changes, so if yours isn’t here, apply and we’ll check.

Is a drug injury claim the same as medical malpractice?

Usually not. A drug claim is against the company that made the drug. If a doctor’s error caused your harm instead, that’s malpractice, and your lawyer will tell you which you have.

What can a drug case advance be worth, and how long will I wait?

Advances run between $500 and $250,000+, depending on your claim’s value and stage. Expect three to five years, sometimes more. Taking a smaller sum first and more later keeps the total lower.

My case is in an MDL. Does that matter?

Most drug cases are, and it doesn’t stop funding. We base the advance on your own claim, not on when the whole MDL ends. What counts is the state where it was first filed.

Apply for Defective Drug Lawsuit Loans

Don’t let a drug company wait you out. Send us the drug’s name, your court and your lawyer’s contact details. Their office and ours take it from there.

There’s no cost to apply, and you can turn down any offer. Questions first? Call us.

The drug claims here are allegations still being argued in court. Nothing here says any drug caused any illness, and it isn’t legal or medical advice. Each advance is non-recourse.

Sources

Links checked October 21, 2026. Ask your lawyer how these affect your own case.